Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
0.5616
-0.0513 (-8.37%)
At close: May 15, 2025, 4:00 PM
0.5700
+0.0084 (1.50%)
After-hours: May 15, 2025, 4:14 PM EDT
Imunon Employees
Imunon had 25 employees as of December 31, 2024. The number of employees decreased by 8 or -24.24% compared to the previous year.
Employees
25
Change (1Y)
-8
Growth (1Y)
-24.24%
Revenue / Employee
n/a
Profits / Employee
-$711,728
Market Cap
8.62M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IMNN News
- 8 hours ago - IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 - GlobeNewsWire
- 3 days ago - Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 days ago - IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewsWire
- 9 days ago - IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology - GlobeNewsWire
- 10 days ago - IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 - GlobeNewsWire
- 24 days ago - IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting - GlobeNewsWire
- 7 weeks ago - IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewsWire